Trials / Enrolling By Invitation
Enrolling By InvitationNCT04138927
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib disodium | Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg. |
Timeline
- Start date
- 2019-10-30
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
- First posted
- 2019-10-25
- Last updated
- 2022-03-17
Locations
37 sites across 18 countries: United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Italy, Netherlands, Norway, Russia, Serbia, Spain, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04138927. Inclusion in this directory is not an endorsement.